替普瑞酮对预防非甾体抗炎药相关性溃疡复发的临床研究  

Clinical research of teprenone to prevent recurrence of NSAIDs-related ulcer

作　　者：郭淦华 王芳芳 宋丰前[2] 沈建冲 陆备军 周春飞 叶淑云 

机构地区：[1]浙江省慈溪市第三人民医院消化内科 [2]湖南省娄底市中心医院消化内科

出　　处：《中国临床药理学与治疗学》2012年第7期806-811,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：慈溪市2010年科技计划项目(CN2010012)

摘　　要：目的:比较长期单独使用替普瑞酮、米索前列醇与奥美拉唑预防非甾体抗炎药(NSAIDs)相关性溃疡复发的疗效和安全性。方法:选取107例长期应用NSAIDs所致消化性溃疡的患者,经6～8周的治疗溃疡愈合后,随机分为:替普瑞酮组(38例),长期服用替普瑞酮50mg/次,3次/d;奥美拉唑组(35例),长期服用奥美拉唑20mg/次,2次/d;米索前列醇组(34例),长期服用米索前列醇200μg/次,2次/d;疗程共52周,分别观察和比较3组患者第0～26、27～52周期间溃疡的复发率和不良反应的发生率。结果:第0～26周期间替普瑞酮组、米索前列醇组与奥美拉唑组患者溃疡复发人数分别为5(13.2%)、5(14.3%)、4(11.8%)例,经比较各组间差异无统计学意义(P>0.05);第27～52周期间3组患者溃疡复发人数分别为6(18.2%)、3(10.0%)、4(13.3%)例,经比较各组间差异无统计学意义(P>0.05)。第0～26周期间3组患者发生不良反应的人数分别为5(13.2%)、4(11.4%)、12(35.3%)例,经比较替普瑞酮与奥美拉唑组组间差异无统计学意义(P>0.05),米索前列醇组显著高于其它两组(P<0.05);第27～52周期间3组发生不良反应的人数分别为3(9.1%)、9(30.0%)、10(33.3%)例,经比较奥美拉唑与米索前列醇组显著高于替普瑞酮组(P<0.05)。结论:应用替普瑞酮可显著降低NSAIDs相关性溃疡复发,与长期使用米索前列醇和质子泵抑制剂(PPI)类药物的疗效相同,但相关药物并发症的发生显著减少。AIM： To compare the therapeutic efficacy and safety of use of exclusive long-term Teprenone, Misoprostol and Omeprazole to pre- vent recurrence of NSAIDs-related ulcer. METHODS： 107 cases of patients with NSAIDs- related ulcer were enrolled and randomly divided into three groups after cured by 6-8 weeks treat- ment. The therapeutic Teprenone group（38 ca- ses） was followed by the treatment with long- term use Teprenone （50 mg, tid）. the Ome- prazole group （34 cases） by the exclusive long- term use of Omeprazole （20 mg, bid）; and the Misoprostol group （35 cases） by the exclusive long-term use of misoprostol （200 μg, bid）. During the treatment course of 52 weeks, inci- dence rates of ulcer recurrence and adverse reac- tions of the three groups were measured at the 26th and 52th week. RESULTS： During the period of the first 26 weeks, recurrence cases of the three groups were 5（13. 2%）,5（14. 3G） and 4 （11.8 %）, respectively ; there was no statistically significant difference among the three groups（P 〉0.05）;and the cases during the period of the 27tu and 52^th weeks were 6（18.2%）, 3（10.0%） and 4（13.3%）,respectively,with no statistically difference among the three groups （P 〉 0.05）. Incidence rates of adverse reactions were 5 （13.2%）,4（11.4%）and 12（35.3%）in the three groups respectively 26 weeks, with no during the period of the first statistically significant he- tween Omeprazole and Teprenone groups （P 0.05） but the rate in the Misoprotol group was significantly higher than the other two groups（P d0.05）. From the 2Wh week to the 52th week, adverse reaction rates were 3（9.1%）,9（30.0%） and 10 （33.3%）, respectively, with the rate in Teprenone group was significantly lower than the other two groups （P 〈 0.05）. CONCLU- SION.. Long-term Teprenone is equivalent to PPI or Misoprotol in preventing the recurrence of NSAIDs-related ulcer, and adverse reaction is reduced.

关 键 词：非甾体抗炎药 替普瑞酮 奥美拉唑 米索前列醇 消化性溃疡 复发 

分 类 号：R57[医药卫生—消化系统]